glp-1 drugs covered by medicaid More state programs may soon cover Wegovy, Zepbound Medicare cuts cost of popular
Description
Some data suggest GIP may promote adiposity under certain metabolic conditions
Hosp Physician
Delayed Response of Amylin Levels after an Oral Glucose Challenge in Children with Prader-Willi Syndrome
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Over 75% of health plans and over 50% of employers are moderately or very concerned about off-label use of GLP-1s approved for type 2 diabetes, but awareness of how much current spend is off-label is notably lower: nearly half of employers and a quarter of health plans are unsure
Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR
